Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2017

de Jong D, Roemer MG, Chan JK, Goodlad J, Gratzinger D, Chadburn A, et al. B-Cell and Classical Hodgkin Lymphomas Associated With Immunodeficiency: 2015 SH/EAHP Workshop Report-Part 2. Am J Clin Pathol. 2017;147(2):153-170.

Magro CM, Olson LC, Nuovo G, Solomon GJ. Primary cutaneous interdigitating dendritic cell sarcoma is a morphologic and phenotypic simulator of poorly differentiated metastatic melanoma: A report of 2 cases and review of the literature. Ann Diagn Pathol. 2017;30:59-65.

Xu R, Zhang C, Shin DY, Kim J-, Lalani S, Li N, et al. c-Jun N-Terminal Kinases (JNKs) Are Critical Mediators of Osteoblast Activity In Vivo. J Bone Miner Res. 2017;32(9):1811-1815.

Reina-Campos M, Moscat J, Diaz-Meco M. Metabolism shapes the tumor microenvironment. Curr Opin Cell Biol. 2017;48:47-53.

Huang L, Fernandes H, Zia H, Tavassoli P, Rennert H, Pisapia D, et al. The cancer precision medicine knowledge base for structured clinical-grade mutations and interpretations. J Am Med Inform Assoc. 2017;24(3):513-519.

Van Besien K, Koshy N, Gergis U, Mayer S, Cushing M, Rennert H, et al. Haplo-cord transplant: HLA-matching determines graft dominance. Leuk Lymphoma. 2017;58(6):1512-1514.

Huang FW, Mosquera JM, Garofalo A, Oh C, Baco M, Amin-Mansour A, et al. Exome Sequencing of African-American Prostate Cancer Reveals Loss-of-Function Mutations. Cancer Discov. 2017;7(9):973-983.

De Robertis M, Loiacono L, Fusilli C, Poeta ML, Mazza T, Sanchez M, et al. Dysregulation of EGFR Pathway in EphA2 Cell Subpopulation Significantly Associates with Poor Prognosis in Colorectal Cancer. Clin Cancer Res. 2017;23(1):159-170.

Isella C, Brundu F, Bellomo SE, Galimi F, Zanella E, Porporato R, et al. Selective analysis of cancer-cell intrinsic transcriptional traits defines novel clinically relevant subtypes of colorectal cancer. Nat Commun. 2017;8:15107.

Posch F, Gebhart J, Rand JH, Koder S, Quehenberger P, Pengo V, et al. Cardiovascular risk factors are major determinants of thrombotic risk in patients with the lupus anticoagulant. BMC Med. 2017;15(1):54.